Targeting insulin and insulin-like growth factor signalling in oncology

被引:77
作者
Pollak, Michael [1 ]
机构
[1] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada
关键词
D O I
10.1016/j.coph.2008.07.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The family of insulin/insulin-like growth factor (IGF) receptors regulates many crucial aspects of cellular and whole-organism physiology. Evidence that targeting these receptors may be useful in cancer treatment was first recognized more than 20 years ago. Drug development began relatively recently, justified both by laboratory studies and by circumstantial clinical evidence that this receptor family is involved in the molecular pathophysiology of neoplasia. Pharmacologic targeting strategies include both small molecule receptor tyrosine kinase inhibitors and anti-receptor antibodies. More than a dozen drug candidates have been studied preclinically, and several are now being evaluated in clinical trials. These trials have provided evidence suggesting safety of the anti-IGF-I receptor antibodies, a few anecdotes of impressive single-agent activity, and early evidence for a significant improvement in response rate to chemotherapy for lung cancer with co-administration of an anti-IGF-I receptor antibody. This experience has justified expanded clinical trials programs to evaluate several of the IGF-I receptor targeting agents in many different areas of clinical need. Most of these trials will involve assessing activity of rational combinations of IGF-I receptor targeting agents with currently approved drugs.
引用
收藏
页码:384 / 392
页数:9
相关论文
共 50 条
  • [31] Targeting insulin-like growth factor in breast cancer therapeutics
    Karamouzis, Michalis V.
    Papavassiliou, Athanasios G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (01) : 8 - 17
  • [32] Targeting the insulin-like growth factor pathway in hepatocellular carcinoma
    Enguita-German, Monica
    Fortes, Puri
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (10) : 716 - 737
  • [33] Role of insulin-like growth factor 1 receptor signalling in cancer
    O Larsson
    A Girnita
    L Girnita
    British Journal of Cancer, 2005, 92 : 2097 - 2101
  • [34] The Insulin-like Growth Factor Signalling Pathway in Cardiac Development and Regeneration
    Diaz del Moral, Sandra
    Benaouicha, Maha
    Munoz-Chapuli, Ramon
    Carmona, Rita
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [35] Role of insulin-like growth factor 1 receptor signalling in cancer
    Larsson, O
    Girnita, A
    Girnita, L
    BRITISH JOURNAL OF CANCER, 2005, 92 (12) : 2097 - 2101
  • [36] Insulin and insulin-like growth factor signalling in neoplasia (vol 8, pg 915, 2008)
    Pollak, Michael
    NATURE REVIEWS CANCER, 2009, 9 (03) : 224 - 224
  • [37] Immunohistochemical analysis of insulin-like growth factor I, insulin-like growth factor I receptor and insulin-like growth factor II in endometriotic tissue and endometrium
    Chang, SY
    Ho, YS
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1997, 76 (02) : 112 - 117
  • [38] Targeting Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Protein-3 Signaling Pathways
    Lee, Hyun
    Kim, So Ri
    Oh, Youngman
    Cho, Seong Ho
    Schleimer, Robert P.
    Lee, Yong Chul
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2014, 50 (04) : 667 - 677
  • [39] Ancient divergence of insulin and insulin-like growth factor
    McRory, JE
    Sherwood, NM
    DNA AND CELL BIOLOGY, 1997, 16 (08) : 939 - 949
  • [40] Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
    Gualberto, Antonio
    Pollak, Michael
    CURRENT DRUG TARGETS, 2009, 10 (10) : 923 - 936